What Researchers Did
The authors reviewed what is known about zygomycosis, a fungal infection, including its causes, risk factors, forms of disease and treatment.
What They Found
This review article reports that infections caused by Zygomycetes have risen significantly over the past decade, mainly in people with weakened immune systems. Patients with diabetes, cancer, solid organ or bone marrow transplants, or iron overload are at highest risk, as are those taking immunosuppressive drugs, deferoxamine, or broad-spectrum antibiotics. The disease can range from a superficial infection to an angioinvasive infection with high mortality. The review describes a three-part treatment strategy: antifungal drugs, surgery, and control of underlying diseases. Lipid formulations of amphotericin B are the antifungal agents of choice, and posaconazole may become approved for treatment. The clinical experience with colony-stimulating factors, interferon-gamma, and hyperbaric oxygen therapy is still limited.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This is a narrative review rather than a trial, and the abstract reports no data on hyperbaric oxygen outcomes, so it cannot show whether HBOT changes results for patients.